DK1337525T3 - Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol - Google Patents

Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol

Info

Publication number
DK1337525T3
DK1337525T3 DK01998545.6T DK01998545T DK1337525T3 DK 1337525 T3 DK1337525 T3 DK 1337525T3 DK 01998545 T DK01998545 T DK 01998545T DK 1337525 T3 DK1337525 T3 DK 1337525T3
Authority
DK
Denmark
Prior art keywords
lansoprazole
crystal
crystallizing
production method
present
Prior art date
Application number
DK01998545.6T
Other languages
English (en)
Inventor
Tadashi Urai
Hideo Hashimoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18838123&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1337525(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of DK1337525T3 publication Critical patent/DK1337525T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01998545.6T 2000-12-01 2001-11-30 Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol DK1337525T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000367757 2000-12-01
PCT/JP2001/010462 WO2002044167A1 (en) 2000-12-01 2001-11-30 Process for the crystallization of (r)- or (s)-lansoprazole

Publications (1)

Publication Number Publication Date
DK1337525T3 true DK1337525T3 (da) 2011-09-19

Family

ID=18838123

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01998545.6T DK1337525T3 (da) 2000-12-01 2001-11-30 Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol

Country Status (17)

Country Link
US (2) US7285668B2 (da)
EP (2) EP2345650A1 (da)
KR (3) KR100939948B1 (da)
CN (1) CN1254473C (da)
AT (1) ATE511508T1 (da)
AU (1) AU2002218506A1 (da)
CA (1) CA2436825C (da)
CY (1) CY1112347T1 (da)
DK (1) DK1337525T3 (da)
ES (1) ES2367419T3 (da)
HK (1) HK1054380B (da)
HU (1) HU229356B1 (da)
NO (1) NO326019B1 (da)
PL (3) PL214684B1 (da)
PT (1) PT1337525E (da)
TW (1) TWI290922B (da)
WO (1) WO2002044167A1 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020027315A1 (en) * 2000-03-10 2002-03-07 Parker Gerard E. Low-firing temperature method for producing Al2O3 bodies having enhanced chemical resistance
DK1293507T3 (da) 2000-05-15 2007-12-27 Takeda Pharmaceutical Fremgangsmåde til fremstilling af krystaller
MXPA04009384A (es) * 2002-03-27 2005-01-25 Teva Pharma Polimorfos de lansoprazol y proceso para la preparacion de los mismos.
AU2003273000A1 (en) * 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
CA2514575A1 (en) * 2003-01-31 2004-08-12 Teijin Pharma Limited Crystal of (23s)-1.alpha.-hydroxy-27-nor-25-methylenevitamin d3-26,23-lactone and process for producing the same
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
JP2006528182A (ja) * 2003-07-18 2006-12-14 サンタラス インコーポレイティッド 薬学的製剤および酸に起因する消化器疾患の治療法
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
EP1967183A4 (en) 2005-12-28 2011-02-23 Takeda Pharmaceutical SOLID PREPARATION WITH CONTROLLED RELEASE
KR100758600B1 (ko) 2006-01-05 2007-09-13 주식회사 대웅제약 란소프라졸 결정형 ａ의 제조방법
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US9486446B2 (en) 2006-12-28 2016-11-08 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
WO2008087665A2 (en) * 2007-01-18 2008-07-24 Matrix Laboratories Ltd Process for preparation of lansoprazole
KR101303813B1 (ko) 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
CN102014638A (zh) * 2007-10-12 2011-04-13 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
NZ593629A (en) * 2007-12-18 2012-11-30 Watson Pharma Private Ltd Stable amorphous R-lansoprazole prepared by optically resolving racemic lansoprazole
GEP20125649B (en) * 2008-03-10 2012-09-25 Takeda Pharmaceutical Benzimidazole compound crystal
US8362042B2 (en) * 2008-05-14 2013-01-29 Watson Pharma Private Limited Stable R(+)-lansoprazole amine salt and a process for preparing the same
US20100113527A1 (en) * 2008-09-30 2010-05-06 Teva Pharmaceutical Industries Ltd. Crystalline forms of dexlansoprazole
WO2010056059A2 (en) * 2008-11-14 2010-05-20 Hanmi Pharm. Co., Ltd. Novel crystalline dexlansoprazole and pharmaceutical composition comprising same
IT1391776B1 (it) * 2008-11-18 2012-01-27 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo
WO2010095144A2 (en) * 2009-02-04 2010-08-26 Msn Laboratories Limited Process for the preparation of proton pump inhibitors
IT1392813B1 (it) 2009-02-06 2012-03-23 Dipharma Francis Srl Forme cristalline di dexlansoprazolo
US20110009637A1 (en) * 2009-02-10 2011-01-13 Dario Braga Crystals of Dexlansoprazole
WO2011004387A2 (en) 2009-06-18 2011-01-13 Matrix Laboratories Ltd Process for the preparation of dexlansoprazole polymorphic forms
IT1395118B1 (it) * 2009-07-29 2012-09-05 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
EP2528912A1 (en) 2010-01-29 2012-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline forms of dexlansoprazole
EP2552904A1 (en) 2010-03-31 2013-02-06 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
WO2011121546A1 (en) 2010-03-31 2011-10-06 Ranbaxy Laboratories Limited Salts of dexlansoprazole and their preparation
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
PE20140005A1 (es) 2010-12-03 2014-01-23 Takeda Pharmaceutical Tableta oralmente desintegradora
MX2013007588A (es) 2010-12-27 2013-08-09 Takeda Pharmaceutical Comprimido de desintegracion oral.
WO2012104805A1 (en) 2011-02-01 2012-08-09 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
EP2723728A1 (en) 2011-06-21 2014-04-30 Ranbaxy Laboratories Limited Process for the preparation of dexlansoprazole
CN102234265B (zh) * 2011-08-08 2013-11-20 天津市汉康医药生物技术有限公司 兰索拉唑化合物
TWI630002B (zh) 2011-11-30 2018-07-21 武田藥品工業股份有限公司 乾塗覆錠
JP5934380B2 (ja) 2011-12-29 2016-06-15 インテル コーポレイション 可変の深さ圧縮
WO2013140120A1 (en) 2012-03-22 2013-09-26 Cipla Limited Glycerol solvate forms of (r) - 2 - [ [ [3 -methyl -4 (2,2, 2 - trifluoroethoxy) pyridin- 2 - yl] methyl] sulphinyl] - 1h - ben zimidazole
WO2013179194A1 (en) 2012-05-31 2013-12-05 Ranbaxy Laboratories Limited Process for the preparation of crystalline dexlansoprazole
KR20160010595A (ko) 2013-05-21 2016-01-27 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴정
CN103254174B (zh) * 2013-06-05 2014-06-11 湖北济生医药有限公司 一种兰索拉唑化合物及其药物组合物
US9920196B2 (en) 2013-06-20 2018-03-20 Japan Polypropylene Corporation Propylene-based block copolymer
CN104958276A (zh) * 2015-07-30 2015-10-07 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物兰索拉唑组合物胶囊
CN104997739A (zh) * 2015-08-31 2015-10-28 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化***疾病的药物兰索拉唑组合物冻干粉针剂
CN105399728B (zh) * 2015-12-20 2017-11-28 寿光富康制药有限公司 一种适用于工业化生产的右兰索拉唑的处理方法
CN106279107A (zh) * 2016-08-10 2017-01-04 成都尚药科技有限公司 一种右旋兰索拉唑晶型的制备方法
CN106749182A (zh) * 2016-11-08 2017-05-31 山东裕欣药业有限公司 一种右旋兰索拉唑晶型化合物及其制备方法
IT201700050223A1 (it) 2017-05-09 2018-11-09 Dipharma Francis Srl Procedimento per la preparazione di dexlansoprazolo cristallino
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
JPH1085502A (ja) * 1996-09-19 1998-04-07 Konica Corp 晶析方法
JP3828648B2 (ja) 1996-11-14 2006-10-04 武田薬品工業株式会社 ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法
TW385306B (en) 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
TR199901101T2 (xx) * 1996-11-22 1999-07-21 The Procter & Gamble Company Gastroenstentinal hastal�klar�n tedavisine y�nelik bizmut ve nsaid i�eren bile�imler.
EP1056457A4 (en) * 1998-01-30 2006-10-25 Sepracor Inc S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE
JP4536905B2 (ja) * 1999-06-17 2010-09-01 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
JP3283252B2 (ja) * 1999-06-17 2002-05-20 武田薬品工業株式会社 ベンズイミダゾール化合物の結晶
TWI289557B (en) * 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
CA2375091A1 (en) * 1999-06-30 2001-01-11 Takeda Chemical Industries, Ltd. Crystals of benzimidazole compounds
JP2001039975A (ja) * 1999-07-26 2001-02-13 Eisai Co Ltd スルホキシド誘導体の結晶およびその製造法
AU6727700A (en) 1999-08-25 2001-03-19 Takeda Chemical Industries Ltd. Process for the preparation of optically active sulfoxide derivatives
EP1277752B1 (en) 2000-04-28 2006-11-22 Takeda Pharmaceutical Company Limited Process for producing optically active sulfoxide derivative
DK1293507T3 (da) 2000-05-15 2007-12-27 Takeda Pharmaceutical Fremgangsmåde til fremstilling af krystaller
CN1117747C (zh) * 2000-06-19 2003-08-13 中国科学院成都有机化学研究所 光学纯兰索拉唑的制备方法

Also Published As

Publication number Publication date
EP1337525B1 (en) 2011-06-01
EP1337525B8 (en) 2011-10-05
US7285668B2 (en) 2007-10-23
AU2002218506A1 (en) 2002-06-11
KR100887912B1 (ko) 2009-03-12
CA2436825C (en) 2011-01-18
HK1054380A1 (da) 2003-11-28
HU229356B1 (en) 2013-11-28
CN1478086A (zh) 2004-02-25
CN1254473C (zh) 2006-05-03
US20080306118A1 (en) 2008-12-11
NO20032437L (no) 2003-07-17
NO326019B1 (no) 2008-09-01
WO2002044167A1 (en) 2002-06-06
PT1337525E (pt) 2011-09-01
KR20100002278A (ko) 2010-01-06
US20040049045A1 (en) 2004-03-11
CA2436825A1 (en) 2002-06-06
NO20032437D0 (no) 2003-05-28
KR100939948B1 (ko) 2010-02-04
PL399787A1 (pl) 2012-11-05
CY1112347T1 (el) 2015-12-09
PL362801A1 (en) 2004-11-02
TWI290922B (en) 2007-12-11
EP2345650A1 (en) 2011-07-20
EP1337525A1 (en) 2003-08-27
ATE511508T1 (de) 2011-06-15
HK1054380B (zh) 2012-01-27
KR20090003348A (ko) 2009-01-09
KR20030060967A (ko) 2003-07-16
ES2367419T3 (es) 2011-11-03
HUP0400781A3 (en) 2010-03-29
HUP0400781A2 (hu) 2004-07-28
PL409463A1 (pl) 2016-02-15
PL214684B1 (pl) 2013-09-30

Similar Documents

Publication Publication Date Title
DK1337525T3 (da) Fremgangsmåde til krystallisering af (R)- eller (S)-lansoprazol
DK0573848T3 (da) Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
DE60105113D1 (de) Verfahren zur Herstellung von einem Kristallepoxid
DE60235089D1 (de) Verfahren zur stabilisierung von reduziertem coenzym q10 und verfahren zur sauren kristallisation
NO20005660D0 (no) Nye mellomprodukter og fremgangsmåter for fremstilling av optisk aktive oktansyrederivater
DE60316791D1 (de) Verfahren zur aufreinigung von lanzoprazol
HUP0302530A2 (hu) Eljárás 2-nitro-4-metilszulfonil-benzoesav tisztítására
DE60104687D1 (de) Mikrofiltration unter verwendung von aktivkohle
DK1213294T3 (da) Fremgangsmåde til rensning af phosphatidylserin
DE50104094D1 (de) Verfahren zur Herstellung von reinem Triethylendiamin (TEDA)
BR9913720A (pt) Processo de purificação por cristalização ourecristalização de ácidos carboxìlicos
ATE115547T1 (de) Verfahren zur reinigung von tetraacetylethylendiamin (taed).
DK0782996T3 (da) Fremgangsmåde til fremstilling af N-biphenylmethylthiadiazolinderivat eller salt deraf og mellemprodukt til fremstilling af
DK1307101T3 (da) Fremgangsmåde til fremstilling af et biocidtkoncentrat
ATE88999T1 (de) Reinigung von isothiazolonen.
DK1091001T3 (da) Fremgangsmåde til rensning af S-adenosyl-L-methionin og til fremstilling af farmaceutiske acceptable salte deraf
DE60019723D1 (de) Eine methode zur herstellung von verbindungen der formel 1 und derivaten
TH57580B (th) วิธีการผลิตผลึก
ATE387420T1 (de) Verfahren zur reinigung von einer alpha- hydroxysäure auf industrieller basis
DE60233541D1 (de) Verfahren zur Reinigung von 5'-geschützten 2'-Deoxypurin Nukleosiden
DE60023232D1 (de) Kristallisierung von Alpha-L-Aspartyl-L-Phenylalaninmethylester aus übersättigten Lösungen
DK1462439T3 (da) Hidtil ukendte stabile krystaller af substitueret phenylpropionsyrederivat og fremgangsmåder til fremstilling af den samme
DE602004028230D1 (de) Verfahren zur Reinigung und zur Herstellung von Phosphorsäure
ATE264314T1 (de) Benzoxazol-derivate, verfahren zu ihrer herstellung und herbizide
DE60201145D1 (de) Verfahren zur Reinigung von 5'-geschützten Thymidinen